Abstract: Objective   To explore the predictive value of platelet lymphocyte ratio (PLR) combined with systemic inflammatory response index (SIRI) in the recurrence of non muscle invasive bladder tumor after plasma resection. Methods   From January 2020 to June 2021,108 patients with nonmuscular invasive bladder tumor were treated in Hai’an People’s Hospital.The levels of neutrophils,lymphocytes,platelets,and monocytes were detected within 24 hours before plasma electroresection,and the SIRI and PLR levels were calculated.The patients were followed up for 12 months and divided into relapse group and non relapse group according to the recurrence outcome.To analyze the influencing factors of postoperative recurrence of patients with nonmuscular invasive bladder tumor,draw the ROC,and use the area under the curve (AUC) to evaluate the predictive efficacy of PLR and SIRI on postoperative recurrence of patients with nonmuscular invasive bladder tumor. Results   By the end of follow-up,7 of 108 patients with nonmuscular invasive bladder tumors had lost follow-up,with a follow-up rate of 93.52%.16 cases recurred,the recurrence rate was 15.84%,and 85 cases (84.16%) had no recurrence detected.The age,SIRI,PLR,tumor stage T1,multiple tumors,and high risk ratio in the recurrence group were higher than those in the non recurrence group (P<0.05).Logistic analysis showed that older age,tumor stage T1,multiple tumors,high risk degree,elevated SIRI and PLR levels were all risk factors for postoperative recurrence of patients with nonmuscular invasive bladder tumor (P<0.05).ROC analysis showed that AUC of patients with nonmuscular invasive bladder tumor predicted by single and combined SIRI and PLR levels were 0.748 (95%CI:0.640～0.855),0.790 (95%CI:0.669～0.911) and 0.819 (95%CI:0.713～0.925) respectively. Conclusion   SIRI and PLR can be used to predict the risk of postoperative recurrence in patients with nonmuscular invasive bladder tumor,and the prediction effect is good.

Key words: non muscle invasive bladder tumor, platelet lymphocyte ratio, systemic inflammatory response index